Breakthrough drug targets ‘undruggable’ cancer, doubles survival in pancreatic cancer
A large trial shows the experimental drug daraxonrasib inhibits all three RAS family proteins and nearly doubles survival in advanced pancreatic cancer (13.2 months vs 6.7 with chemotherapy), marking a breakthrough against previously undruggable targets and highlighting prospects for combination therapies and broader use in hard-to-treat tumors.